Vanguard Personalized Indexing Management LLC Has $2.07 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Vanguard Personalized Indexing Management LLC lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 22.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,503 shares of the biotechnology company’s stock after buying an additional 1,187 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in United Therapeutics were worth $2,069,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. ClariVest Asset Management LLC raised its holdings in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in United Therapeutics in the 2nd quarter worth about $30,000. Innealta Capital LLC acquired a new position in United Therapeutics in the 2nd quarter worth about $33,000. Rise Advisors LLC acquired a new position in United Therapeutics in the 1st quarter worth about $32,000. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on UTHR shares. UBS Group upped their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Bank of America lowered their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Finally, TD Cowen upped their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $350.36.

United Therapeutics Stock Up 0.5 %

Shares of United Therapeutics stock opened at $353.00 on Friday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $366.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The stock’s 50-day moving average is $338.55 and its 200 day moving average is $290.39. The firm has a market cap of $15.70 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same quarter in the previous year, the company earned $5.24 EPS. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current year.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 266 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now owns 5,107 shares in the company, valued at approximately $1,626,988.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other United Therapeutics news, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the transaction, the director now owns 5,107 shares in the company, valued at $1,626,988.06. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $41,076.10. The disclosure for this sale can be found here. Insiders have sold a total of 110,922 shares of company stock worth $36,541,398 in the last 90 days. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.